Personalized Therapy for Non-Small Cell Lung Cancer: Which Drug for Which Patient?

Seminars in Thoracic and Cardiovascular Surgery

Volumn 23, Issue 4, 2011, Pages 281-290

  Villaruz, Liza C ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Non small cell lung cancer; Targeted therapy

Indexed keywords

AFATINIB; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EMEPEPIMUT S; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; MELANOMA ANTIGEN 3; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR PATHOLOGY; MONOTHERAPY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PROGRESSION FREE SURVIVAL; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PHARMACOGENETICS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84858740707     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2012.01.001     Document Type: Article

References (85)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER stat fact sheets: Lung and bronchus Accessed November 11, 2011. http://seercancergov/csr/1975_2008/.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
3. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6:633-641.
4. Hopwood P., Stephens R.J. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment-The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995, 71:633-636.
5. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909. Non-small Cell Lung Cancer Collaborative Group.
6. Burdett S., Stewart L., Pignon J.-P. Chemotherapy in non-small cell lung cancer: An update of an individual patient data-based meta-analysis. J Thorac Cardiovasc Surg 2005, 129:1205.
7. Burdett S., Stephens R., Stewart L., et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
8. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
9. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
10. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
11. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
12. Zatloukal P., Petruzelka L., Zemanová M., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003, 41:321-331.
13. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
14. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
15. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995, 36:127-137.
16. Mattern J., Koomägi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73:931-934.
17. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53:4727-4735.
18. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91.
19. Seto T., Higashiyama M., Funai H., et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006, 53:91-96.
20. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
21. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
22. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
23. Reck M., von Pawel J., Zatloukal P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
24. Dahlberg S.E., Sandler A.B., Brahmer J.R., et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010, 28:949-954.
25. Sharma S.V., Bell D.W., Settleman J., et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
26. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
27. Fukuoka M., Wu Y.L., Thongprasert S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
28. Lee J., Park K., Kim S.-W., et al. A randomized phase III study of gefitnib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thoracic Oncol 2009, 4:S283.
29. Rosell R., Gervais R., Vergnenegre A., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. ASCO Meeting Abstracts 2011, 29:7503.
30. Zhou C., Wu Y.-L., Chen G., et al. Efficacy results from the randomised phase III Optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. ESMO Late Breaking Abstracts 2010, 21:LBA13.
31. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
32. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
33. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
34. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
35. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
36. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
37. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
38. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
39. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
40. Lynch T.J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
41. Herbst R.S., Ansari R., Bustin F., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
42. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
43. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
44. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
45. Miller V., Hirsh V., Cadranel J., et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) 1 best supportive care (BSC) versus placebo 1 BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). Ann Oncol 2010, 21:LBA1.
46. Chiarle R., Voena C., Ambrogio C., et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
47. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
48. Soda M., Takada S., Takeuchi K., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008, 105:19893-19897.
49. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
50. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
51. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. ASCO Meeting Abstracts 2011, 29:7507.
52. Goss G.D., Lorimer I., Tsao M.S., et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. ASCO Meeting Abstracts 2010, 28:LBA7005.
53. Raez L.E., Fein S., Podack E.R. Lung cancer immunotherapy. Clin Med Res 2005, 3:221-228.
54. Abu-Shakra M., Buskila D., Ehrenfeld M., et al. Cancer and autoimmunity: Autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001, 60:433-441.
55. Novellino L., Castelli C., Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005, 54:187-207.
56. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003, 21:807-839.
57. Hirschowitz E.A., Hiestand D.M., Yannelli J.R. Vaccines for lung cancer. J Thorac Oncol 2006, 1:93-104.
58. De Plaen E., Arden K., Traversari C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
59. Vansteenkiste J., Zielinski M., Linder A., et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2007, 25:7554.
60. Ho S.B., Niehans G.A., Lyftogt C., et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993, 53:641-651.
61. Butts C., Murray N., Maksymiuk A., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681.
62. Mu D., Hsu D.S., Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996, 271:8285-8294.
63. Sancar A. Mechanisms of DNA excision repair. Science 1994, 266:1954-1956.
64. Zamble D.B., Mu D., Reardon J.T., et al. Repair of cisplatinDNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
65. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
66. Davidson J.D., Ma L., Flagella M., et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766.
67. Bergman A.M., Eijk P.P., Ruiz van Haperen V.W., et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65:9510-9516.
68. Bepler G., Kusmartseva I., Sharma S., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
69. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746.
70. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
71. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
72. Takezawa K., Okamoto I., Okamoto W., et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011, 104:1594-1601.
73. Anders C.K., Winer E.P., Ford J.M., et al. Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer. Clin Cancer Res 2010, 16:4702-4710.
74. Taron M., Rosell R., Felip E., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-2449.
75. Quinn J.E., James C.R., Stewart G.E., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13:7413-7420.
76. O'Byrne K.J., Bondarenko I., Barrios C., et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. ASCO Meeting Abstracts 2009, 27:8007.
77. Douillard J.Y., Shepherd F.A., Hirsh V., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
78. Kawano O., Sasaki H., Endo K., et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54:209-215.
79. Yamamoto H., Shigematsu H., Nomura M., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68:6913-6921.
80. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
81. Onozato R.M.D., Kosaka T.M.D., Kuwano H.M.D., et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009, 4:5-11.
82. Paik P.K., Arcila M.E., Fara M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051.
83. Dziadziuszko R., Merrick D.T., Witta S.E., et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: A comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010, 28:2174-2180.
84. Lynch T.J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
85. Crino L., Kim D., Riely G.J., et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. ASCO Meeting Abstracts 2011, 29:7514.